Poseida Therapeutics, which is testing CAR-T cell therapies for blood-borne and solid tumor cancers, has laid the groundwork for an initial public offering.
In documents filed with securities regulators Friday, the San Diego company set a preliminary IPO target of $115 million. The company has applied for a listing on the Nasdaq stock exchange under the symbol “PSTX.”
CAR-T therapies deploy T cells that have been engineered to kill cancer. These cells, programmed to act aggressively, have in some cases led to significant side effects, however. Results for the first two CAR-T products approved, both in 2017, have varied…. Read more »
UNDERWRITERS AND PARTNERS